Parallel Advisors’s Larimar Therapeutics LRMR Stock Holding History

Parallel Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$869	Hold	193	–	–	﹤0.01%	3563
2025 Q4	$735	Buy	+193	New	+$751	﹤0.01%	3353

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Parallel Advisors's LRMR Position: Q1 2026 in Review

Parallel Advisors held its Larimar Therapeutics (LRMR) position steady in Q1 2026 at 193 shares worth $869. The position accounts for ﹤0.01% of the portfolio, ranked #3563.

Parallel Advisors first reported a position in LRMR in Q4 2025 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

Parallel Advisors held 193 shares of Larimar Therapeutics worth $869 as of Q1 2026.
Parallel Advisors left its Larimar Therapeutics share count unchanged in Q1 2026.
Larimar Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3563 holding.
Parallel Advisors first reported a position in Larimar Therapeutics in Q4 2025 and has held it in 2 quarters since.
162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.